Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers

Cardiac imaging with echocardiography should be considered in the follow-up period in all survivors at high risk for cardiomyopathy. For the last 4 decades, oncologists have been aware that some cancer treatments, particular chemotherapeutic agents and radiation, can result in cardiovascular complications, such as ischemic cardiovascular disease, cardiomyopathy, clinical heart failure, and arrhythmias. Although treatments options for patients with cancer have evolved with the introduction of new targeted therapies, there continues to be a growing appreciation of the cardiac toxicities of cancer therapies—thus the emergence of a new field of “cardio-oncology.”1-3 In parallel, there has been a rapid growth in the biologic understanding of cancer, molecular pathways, genetic susceptibility to cancer, and cancer syndromes as well as the toxicities of these therapies.4 Here, we present an overview of the development of cardio-oncology, the cardiac toxicity of new anticancer agents, and newer techniques, such as imaging and biomarkers, that can be used for the monitoring and prevention of cardiac complications of anticancer therapies. CARDIAC TOXICITIES IN THE ERA OF PRECISION MEDICINE Section: ChooseTop of pageAbstractCARDIAC TOXICITIES IN THE... <